Open AccessEffect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors
Author(s) -
Wadi Mawad,
Luc Mertens,
Joseph J Pagano,
Eugénie Riesenkampff,
Marjolein J. E. Reichert,
Seema Mital,
Paul F. Kantor,
Mark Greenberg,
Peter Liu,
Paul C. Nathan,
Lars Grosse-Wortmann
Publication year - 2020
Publication title -
european heart journal. cardiovascular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.576
H-Index - 92
eISSN - 2047-2412
pISSN - 2047-2404
DOI - 10.1093/ehjci/jeaa093
Subject(s) - medicine , ejection fraction , cardiology , cohort , asymptomatic , anthracycline , diastole , extracellular fluid , myocardial fibrosis , cancer , fibrosis , heart failure , extracellular , breast cancer , blood pressure , biology , microbiology and biotechnology
Anthracyclines are a cornerstone of paediatric cancer treatment. We aimed to quantify myocardial cardiac magnetic resonance (CMR) native T1 (NT1) and extracellular volume fraction (ECV) as markers of fibrosis in a cohort of childhood cancer survivors (CCS).